Subtopic Deep Dive
Genetic Mutations in Glomus Tumors
Research Guide
What is Genetic Mutations in Glomus Tumors?
Genetic mutations in glomus tumors are somatic and germline alterations, primarily in NF1 and GLMN genes, driving pathogenesis of these perivascular soft tissue tumors often linked to neurofibromatosis type 1 (NF1).
Glomus tumors arise from glomus bodies and feature mutations like NF1 loss-of-function variants and GLMN frameshifts (Brems et al., 2009; Brouillard et al., 2005). Studies document NF1 germline carriers developing multiple glomus tumors, establishing a novel NF1 association (Brems et al., 2009, 135 citations). Approximately 10 papers from provided lists address this, focusing on mutational spectra and familial syndromes.
Why It Matters
Genetic insights enable NF1 screening for glomus tumor-prone families, improving early detection (Stewart et al., 2018, 177 citations). Targeted therapies against NF1 pathway aberrations could treat associated tumors, as NF1 mutations drive proliferation in NF1-linked neoplasms (Laycock-van Spyk et al., 2011, 151 citations). In soft tissue sarcoma management, identifying glomus subtypes refines classification and prognosis (Sbaraglia et al., 2020, 925 citations; von Mehren et al., 2016, 298 citations).
Key Research Challenges
Detecting low-frequency somatic mutations
Glomus tumors exhibit heterogeneous NF1 somatic mutations requiring deep sequencing for detection (Brems et al., 2009). Distinguishing tumor-specific variants from germline NF1 changes demands matched normal tissue analysis (Laycock-van Spyk et al., 2011). Over 50 NF1-associated tumors show variable spectra, complicating variant prioritization.
Linking GLMN mutations to phenotypes
Four common GLMN mutations account for two-thirds of glomuvenous malformations, but penetrance varies (Brouillard et al., 2005, 143 citations). Founder effects explain clustering, yet functional impacts on glomus cell proliferation remain unclear. Modeling these in NF1 contexts is limited.
Distinguishing NF1-associated glomus tumors
NF1 germline carriers develop painful subungual glomus tumors, but diagnostic criteria overlap with sporadic cases (Brems et al., 2009). Clinical guidelines stress genetic testing, yet NF1 prevalence underestimates tumor associations (Stewart et al., 2018). Pathological confirmation challenges soft tissue classification (Sbaraglia et al., 2020).
Essential Papers
The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives
Marta Sbaraglia, Elena Bellan, Angelo Paolo Dei Tos · 2020 · Pathologica · 925 citations
Mesenchymal tumours represent one of the most challenging field of diagnostic pathology and refinement of classification schemes plays a key role in improving the quality of pathologic diagnosis an...
Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology
Margaret von Mehren, R. Lor Randall, Robert S. Benjamin et al. · 2016 · Journal of the National Comprehensive Cancer Network · 298 citations
Soft tissue sarcomas (STS) are rare solid tumors of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blo...
The Pathoetiology of Neurofibromatosis 1
Eeva‐Mari Jouhilahti, Sirkku Peltonen, Anthony M. Heape et al. · 2011 · American Journal Of Pathology · 184 citations
Nail biology and nail science
D. A. R. de Berker, Josette André, Robert Baran · 2007 · International Journal of Cosmetic Science · 183 citations
Synopsis The nail plate is the permanent product of the nail matrix. Its normal appearance and growth depend on the integrity of several components: the surrounding tissues or perionychium and the ...
Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)
Douglas R. Stewart, Bruce R. Korf, Katherine L. Nathanson et al. · 2018 · Genetics in Medicine · 177 citations
Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966
Christina Bergqvist, Amandine Servy, L. Valeyrie‐Allanore et al. · 2020 · Orphanet Journal of Rare Diseases · 174 citations
Neurofibromatosis type 1-associated tumours: Their somatic mutational spectrum and pathogenesis
S Laycock-van Spyk, Nick Thomas, D.N. Cooper et al. · 2011 · Human Genomics · 151 citations
Somatic gene mutations constitute key events in the malignant transformation of human cells. Somatic mutation can either actively speed up the growth of tumour cells or relax the growth constraints...
Reading Guide
Foundational Papers
Start with Brems et al. (2009) for NF1-glomus association evidence; Brouillard et al. (2005) for GLMN mutations; Laycock-van Spyk et al. (2011) for somatic spectra in NF1 tumors.
Recent Advances
Sbaraglia et al. (2020) updates WHO classification including glomus entities; Stewart et al. (2018) provides NF1 clinical guidelines relevant to tumor screening.
Core Methods
Sequencing for NF1/GLMN variants; pedigree analysis for germline transmission; histological correlation with perivascular glomus cells (Brems et al., 2009; Brouillard et al., 2005).
How PapersFlow Helps You Research Genetic Mutations in Glomus Tumors
Discover & Search
Research Agent uses searchPapers('glomus tumors NF1 mutations') to retrieve Brems et al. (2009), then citationGraph reveals NF1-glomus links from 135 citing papers, and findSimilarPapers expands to GLMN studies like Brouillard et al. (2005). exaSearch queries 'glomulin mutations familial glomangiomas NF1' for founder effects.
Analyze & Verify
Analysis Agent applies readPaperContent on Brems et al. (2009) to extract NF1 mutation frequencies, verifies NF1-glomus association via verifyResponse (CoVe) against Stewart et al. (2018), and runs PythonAnalysis to plot mutation spectra from parsed abstracts using pandas. GRADE grading scores evidence strength for NF1 causality.
Synthesize & Write
Synthesis Agent detects gaps in GLMN-NF1 interaction studies, flags contradictions between sporadic vs. familial mutations, and uses exportMermaid for NF1 pathway diagrams. Writing Agent employs latexEditText for manuscript sections, latexSyncCitations integrates Brouillard et al. (2005), and latexCompile generates polished reviews.
Use Cases
"Analyze NF1 mutation frequencies in glomus tumors from Brems 2009 and related papers"
Analysis Agent → readPaperContent (Brems et al., 2009) → runPythonAnalysis (pandas frequency table, matplotlib bar plot of NF1 variants) → researcher gets CSV of mutation stats and GRADE-scored evidence summary.
"Draft review section on GLMN mutations in familial glomus tumors with citations"
Synthesis Agent → gap detection (GLMN founder effects) → Writing Agent → latexEditText (intro paragraph) → latexSyncCitations (Brouillard 2005) → latexCompile → researcher gets compilable LaTeX with diagram via exportMermaid.
"Find code for analyzing glomus tumor sequencing data linked to NF1 papers"
Research Agent → searchPapers('glomus NF1 sequencing') → Code Discovery (paperExtractUrls → paperFindGithubRepo → githubRepoInspect) → researcher gets Python scripts for variant calling pipelines tied to Laycock-van Spyk (2011).
Automated Workflows
Deep Research workflow scans 50+ NF1/soft tissue papers via searchPapers → citationGraph → structured report on glomus mutations with GRADE scores. DeepScan applies 7-step analysis: readPaperContent (Brems 2009) → verifyResponse (CoVe on NF1 claims) → runPythonAnalysis (mutation stats). Theorizer generates hypotheses on NF1-GLMN interactions from mutational spectra.
Frequently Asked Questions
What defines genetic mutations in glomus tumors?
Primarily NF1 loss-of-function somatic/germline mutations and GLMN frameshifts, associating tumors with neurofibromatosis type 1 (Brems et al., 2009).
What methods identify these mutations?
Sequencing of tumor DNA detects NF1 variants; founder GLMN mutations identified via pedigree analysis (Brouillard et al., 2005; Laycock-van Spyk et al., 2011).
What are key papers on this topic?
Brems et al. (2009, 135 citations) proves NF1-glomus link; Brouillard et al. (2005, 143 citations) details GLMN mutations (four common variants cause 66% glomuvenous malformations).
What open problems exist?
Functional roles of NF1-GLMN interactions unclear; low-frequency somatic variants need deep sequencing; therapy targets for NF1-driven glomus tumors undefined.
Research Soft tissue tumors and treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Genetic Mutations in Glomus Tumors with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Soft tissue tumors and treatment Research Guide